直肠黄体酮对早产胎膜早破孕妇产妇和新生儿结局的疗效:一项三盲随机临床试验

IF 1.1 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Shohre Vosoogh, Marzieh Zanganeh, Behnaz Gonabadi
{"title":"直肠黄体酮对早产胎膜早破孕妇产妇和新生儿结局的疗效:一项三盲随机临床试验","authors":"Shohre Vosoogh,&nbsp;Marzieh Zanganeh,&nbsp;Behnaz Gonabadi","doi":"10.1515/hmbci-2021-0103","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study was conducted to evaluate the efficacy of rectal progesterone suppositories on pregnancy outcomes of pregnant women diagnosed with PPROM at the gestational age of 26-34 weeks, as well as on maternal and neonatal outcomes.</p><p><strong>Methods: </strong>This is a double-blind, randomized clinical trial in pregnant women with PROM with gestational age of 26-24 weeks, conducted between February 2020 and December 2020 in Sayyad Shirazi Hospital, Gorgan, Iran.</p><p><strong>Results: </strong>According to the results of the present study; Rectal progesterone suppository in pregnant women with PPROM is associated with improved delivery outcomes such as neonatal APGAR score, increased latent delivery stage without complications or severe and dangerous complications, without increased risk of mortality and NICU hospitalization in infants, so prescribing suppository rectal progesterone in pregnant women with PPROM with a gestational age of 26 to 34 weeks is associated with positive outcomes and is recommended based on the findings and opinions of the researchers.</p><p><strong>Conclusions: </strong>According to the results of the present study; Rectal progesterone suppository in pregnant women with PPROM is associated with improved delivery outcomes such as neonatal APGAR score, increased latent delivery stage without complications or severe and dangerous complications, without increased risk of mortality and NICU hospitalization in infants, so prescribing suppository rectal progesterone in pregnant women with PPROM with a gestational age of 26 to 34 weeks is associated with positive outcomes and is recommended based on the findings and opinions of the researchers.</p>","PeriodicalId":13224,"journal":{"name":"Hormone Molecular Biology and Clinical Investigation","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of rectal progesterone on maternal and neonatal outcomes in pregnant women with Preterm Premature Rupture of membranes: a triple-blind randomised clinical trial.\",\"authors\":\"Shohre Vosoogh,&nbsp;Marzieh Zanganeh,&nbsp;Behnaz Gonabadi\",\"doi\":\"10.1515/hmbci-2021-0103\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study was conducted to evaluate the efficacy of rectal progesterone suppositories on pregnancy outcomes of pregnant women diagnosed with PPROM at the gestational age of 26-34 weeks, as well as on maternal and neonatal outcomes.</p><p><strong>Methods: </strong>This is a double-blind, randomized clinical trial in pregnant women with PROM with gestational age of 26-24 weeks, conducted between February 2020 and December 2020 in Sayyad Shirazi Hospital, Gorgan, Iran.</p><p><strong>Results: </strong>According to the results of the present study; Rectal progesterone suppository in pregnant women with PPROM is associated with improved delivery outcomes such as neonatal APGAR score, increased latent delivery stage without complications or severe and dangerous complications, without increased risk of mortality and NICU hospitalization in infants, so prescribing suppository rectal progesterone in pregnant women with PPROM with a gestational age of 26 to 34 weeks is associated with positive outcomes and is recommended based on the findings and opinions of the researchers.</p><p><strong>Conclusions: </strong>According to the results of the present study; Rectal progesterone suppository in pregnant women with PPROM is associated with improved delivery outcomes such as neonatal APGAR score, increased latent delivery stage without complications or severe and dangerous complications, without increased risk of mortality and NICU hospitalization in infants, so prescribing suppository rectal progesterone in pregnant women with PPROM with a gestational age of 26 to 34 weeks is associated with positive outcomes and is recommended based on the findings and opinions of the researchers.</p>\",\"PeriodicalId\":13224,\"journal\":{\"name\":\"Hormone Molecular Biology and Clinical Investigation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hormone Molecular Biology and Clinical Investigation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/hmbci-2021-0103\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Molecular Biology and Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/hmbci-2021-0103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在评估直肠黄体酮栓剂对26-34周诊断为PPROM的孕妇妊娠结局的影响,以及对孕产妇和新生儿结局的影响。方法:这是一项双盲、随机临床试验,研究对象为胎龄为26-24周的胎膜早PROM孕妇,于2020年2月至2020年12月在伊朗戈尔根的Sayyad Shirazi医院进行。结果:根据本研究结果;PPROM孕妇直肠孕酮栓剂可改善分娩结局,如新生儿APGAR评分,增加无并发症或严重危险并发症的潜在分娩期,不增加婴儿死亡率和新生儿重症监护病房住院风险。因此,根据研究人员的发现和意见,建议对胎龄在26至34周的PPROM孕妇使用直肠黄体酮栓剂与积极结果相关。结论:根据本研究结果;PPROM孕妇直肠孕酮栓剂可改善分娩结局,如新生儿APGAR评分,增加无并发症或严重危险并发症的潜在分娩期,不增加婴儿死亡率和新生儿重症监护病房住院风险。因此,根据研究人员的发现和意见,建议对胎龄在26至34周的PPROM孕妇使用直肠黄体酮栓剂与积极结果相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy of rectal progesterone on maternal and neonatal outcomes in pregnant women with Preterm Premature Rupture of membranes: a triple-blind randomised clinical trial.

Objectives: This study was conducted to evaluate the efficacy of rectal progesterone suppositories on pregnancy outcomes of pregnant women diagnosed with PPROM at the gestational age of 26-34 weeks, as well as on maternal and neonatal outcomes.

Methods: This is a double-blind, randomized clinical trial in pregnant women with PROM with gestational age of 26-24 weeks, conducted between February 2020 and December 2020 in Sayyad Shirazi Hospital, Gorgan, Iran.

Results: According to the results of the present study; Rectal progesterone suppository in pregnant women with PPROM is associated with improved delivery outcomes such as neonatal APGAR score, increased latent delivery stage without complications or severe and dangerous complications, without increased risk of mortality and NICU hospitalization in infants, so prescribing suppository rectal progesterone in pregnant women with PPROM with a gestational age of 26 to 34 weeks is associated with positive outcomes and is recommended based on the findings and opinions of the researchers.

Conclusions: According to the results of the present study; Rectal progesterone suppository in pregnant women with PPROM is associated with improved delivery outcomes such as neonatal APGAR score, increased latent delivery stage without complications or severe and dangerous complications, without increased risk of mortality and NICU hospitalization in infants, so prescribing suppository rectal progesterone in pregnant women with PPROM with a gestational age of 26 to 34 weeks is associated with positive outcomes and is recommended based on the findings and opinions of the researchers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hormone Molecular Biology and Clinical Investigation
Hormone Molecular Biology and Clinical Investigation BIOCHEMISTRY & MOLECULAR BIOLOGY-
CiteScore
2.60
自引率
0.00%
发文量
55
期刊介绍: Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements. HMBCI is a blind peer reviewed journal and publishes in English: Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信